```text
Wiki Article
Abciximab (C7E3, 143653-53-6): A Research Reagent Overview
Abciximab, also identified as C7E3 or bearing the CAS number 143653-53-6, is a a valuable research compound extensively utilized in platelet research . This monoclonal antibody fragment specifically targets the glycoprotein IIb/IIIa complex on thrombocytes , preventing platelet aggregation . As a result, it's often applied as a tool to examine the processes underlying clotting and to evaluate the effectiveness of antithrombotic drugs . Distribution is typically restricted to institutional settings.
```
Abciximab Drug Research: Utilizing C7E3 Antibody and The 143653-53-6 Substance in Scientific Assessments
Ongoing research into abciximab, a platelet aggregation inhibitor, frequently utilizes the monoclonal antigen C7E3 and the chemical compound identified as 143653-53-6. These tools are instrumental for analyzing abciximab's mode of function, determining its therapeutic effect in different patient populations, and exploring potential predictors of treatment response. Additional exploration leveraging these precise reagents is expected to generate valuable information for improving clinical applications related to cardiovascular disease.
```text
C7E3 abciximab, also known as c7e3fragment, is a GPIIb/IIIa receptor antagonist widely utilized in scientific research. Its primary application lies in platelet aggregation studies, allowing investigators here to probe the mechanisms underlying thrombosis and hemostasis. Researchers employ this agent to investigate the role of platelet activation in various disease models, including ischemia-reperfusion injury and inflammation. Beyond basic research, abciximab is increasingly used in developing novel antithrombotic therapies and evaluating their efficacy. Furthermore, studies exploring its potential to modulate vascular smooth muscle cell function and reduce intracranial bleeding are ongoing. The availability of c7e3 abciximab facilitates a deeper understanding of platelet-mediated processes and contributes to the advancement of translational medicine. }
```
```text
Investigating Research Opportunities with Abciximab 143653-53-6 and C7E3
Recent work indicate that the drug (identified as 143653-53-6) holds significant research promise, particularly when associated with C7E3. Early observations have that this pairing may boost clinical outcomes in various cardiovascular contexts. Further exploration is centered on understanding the precise process of interaction between this inhibitor and C7E3, involving analysis of blood clot cohesion and arterial preservation.
- Current investigation endeavors intend to maximize dosing protocols.
- Preclinical systems are being utilized to further validate these theories.
- Clinical assessments might be required to fully evaluate patient effectiveness.
```
Abciximab (C7E3) for Research: Quality and Characteristics (143653-53-6)
Researchers needing abciximab for experimental investigations should meticulously assess quality and documented parameters . The compound is typically provided as a solid powder and detailed analytical documentation including assessment by mass spectrometry , potency assays, and bacterial endotoxin testing is available. Verify the source’s documentation specifies defined ranges for impurities and conforms to established QC guidelines.
Research-Grade C7E3 Details & Stock
Acquiring laboratory-grade Abciximab, specifically referencing the molecule C7E3 and identified by the catalog number 143653-53-6, requires thorough consideration of its source . This agent is widely utilized in cell-based studies , particularly those involving platelet aggregation and occlusion. Available vendors offer this reagent in varying amounts , typically ranging from mg to significant bulk amounts . Please suggest reviewing the documentation of testing to verify integrity and suitability for your specific application . Furthermore , check the stability date before obtaining to maintain ideal effectiveness.
- Typical Purity: >95%
- Keeping Conditions: -20°C in suitable conditions
- Use : Platelet Adhesion Inhibition Studies